Financial Performance - Revenue for the third quarter of 2024 was RMB 2,861,505,455.47, an increase of 12.41% year-over-year[2] - Net profit attributable to shareholders for the third quarter was RMB 244,809,564.16, a decrease of 2.19% year-over-year[2] - Operating revenue reached 9,290,220,207.76 RMB, an increase from 8,500,085,529.08 RMB in the same period last year[12] - Operating costs totaled 8,295,069,270.45 RMB, up from 7,444,588,905.92 RMB[12] - Net profit attributable to the parent company's owners was 5,026,026,552.02 RMB, up from 4,520,034,984.41 RMB[11] - Operating profit for the quarter reached 1,023,122,464.97 yuan, a slight increase from 1,013,524,987.41 yuan in the previous period[13] - Net profit attributable to the parent company's shareholders was 869,652,417.71 yuan, up from 851,344,083.86 yuan in the prior period[13] - Sales revenue from goods and services reached 7,470,804,774.82 yuan, a significant rise from 5,986,375,397.51 yuan in the same period last year[14] - Basic earnings per share increased to 0.7466 yuan from 0.7281 yuan in the previous period[13] - Comprehensive income attributable to the parent company's shareholders rose to 873,223,790.05 yuan, compared to 848,248,390.43 yuan in the prior period[13] Cash Flow and Liquidity - Operating cash flow for the first nine months of 2024 was RMB 1,165,709,114.84, an increase of 37.38% year-over-year[2] - Net cash flow from financing activities was RMB -532,530,690.54, a decrease of 72.15% year-over-year, mainly due to increased stock repurchases and dividend payments[5] - Cash flow from operating activities increased to 1,165,709,114.84 yuan, compared to 848,540,440.86 yuan in the previous year[15] - Cash received from tax refunds amounted to 377,272,002.48 yuan, slightly higher than 366,708,211.74 yuan in the previous year[15] - Cash paid for goods and services increased to 5,241,010,944.55 yuan, up from 4,197,997,038.54 yuan in the prior period[15] - Cash flow from investment activities showed a net outflow of 364,538,076.21 yuan, an improvement from a net outflow of 460,801,711.33 yuan in the previous year[15] - Cash and cash equivalents at the end of the period stood at 2,735,557,535.96 yuan, up from 2,495,464,491.45 yuan at the beginning of the period[16] Assets and Liabilities - Total assets as of the end of the third quarter were RMB 13,339,366,342.08, an increase of 4.48% compared to the end of the previous year[2] - Total assets increased to 13,339,366,342.08 RMB, up from 12,767,664,072.34 RMB in the previous period[10] - Total liabilities rose to 6,751,589,006.48 RMB, compared to 6,537,246,876.10 RMB previously[10] - Owner's equity grew to 6,587,777,335.60 RMB, up from 6,230,417,196.24 RMB[11] - The company's monetary funds increased to 3,892,828,335.80 RMB at the end of the period, up from 3,580,686,915.36 RMB at the beginning of the period[9] - Accounts receivable rose to 1,762,610,761.91 RMB, compared to 1,695,032,971.13 RMB at the start of the period[9] - Inventory decreased to 1,844,380,687.82 RMB from 2,083,301,418.08 RMB at the beginning of the period[9] - Fixed assets stood at 2,866,856,667.27 RMB, down from 3,001,108,252.13 RMB at the start of the period[9] - Construction in progress increased to 767,150,754.39 RMB, up from 545,846,228.04 RMB at the beginning of the period[9] - Short-term borrowings increased to 871,965,120.77 RMB, compared to 807,796,237.52 RMB[10] - Accounts payable and advances from customers totaled 1,969,400,370.43 RMB, down from 2,013,890,900.04 RMB[10] - Intangible assets decreased to 312,410,959.01 RMB, from 319,795,853.83 RMB[10] R&D and Investments - R&D investment for the first nine months of 2024 was RMB 467,201,967.23, an increase of 5.26% year-over-year[5] - R&D expenses amounted to 467,201,967.23 RMB, a decrease from 483,755,349.59 RMB[12] - Prepayments increased by 119.94% year-over-year to RMB 565,176,702.21, mainly due to increased prepayments for materials[5] - Other non-current assets increased by 191.79% year-over-year to RMB 156,849,038.35, primarily due to increased prepayments for equipment[5] Shareholder Information - The company repurchased 10,880,000 shares, representing 0.93% of the total shares, through a dedicated securities account[7] - Hengdian Group Holding Co., Ltd. holds 28.30% of the company's shares, totaling 330,941,729 shares[7] - Zhejiang Hengdian Import & Export Co., Ltd. holds 13.39% of the company's shares, totaling 156,552,903 shares[7] - Zhejiang Hengrun Technology Co., Ltd. holds 5.10% of the company's shares, totaling 59,683,845 shares[7] - Hengdian Group Jiayuan Chemical Co., Ltd. holds 3.83% of the company's shares, totaling 44,750,178 shares[7] Government Subsidies and Returns - Government subsidies received during the third quarter amounted to RMB 19,784,103.27[3] - The weighted average return on equity for the first nine months of 2024 was 13.52%, a decrease of 1.25 percentage points year-over-year[2]

证券代码：000739 证券简称：普洛药业 公告编号：2024-47 普洛药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2024年3月27日召开第九届 董事会第五次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司员工持股计划。 本次回购股份价格不超过人民币20元/股（含），回购资金总额不低于人民币1.5 亿元（含）且不超过人民币3亿元（含）。具体回购股份数量以回购期限届满或 回购股份实施完毕时实际回购股份数量为准。回购期限为自公司董事会审议通过 回购股份方案之日起6个月内。具体内容详见公司分别于2024年3月28日、2024 年3月29日在《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）上披露 的《第九届董事会第五次会议决议公告》（公告编号：2024-20）、《关于回购 公司股份方案的公告》（公告编号：2024-21）及《关于回购股份的报告书》（公 告编号：2024-22）。 因公司实施2023年度分红派 ...

证券代码：000739 证券简称：普洛药业 公告编号：2024-46 普洛药业股份有限公司 关于签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次公司与合作方签署的《战略合作协议》，是本着诚信、平等、 双赢的原则开展合作，双方在现有产品、产能和技术上实现优势互补、强强 合作，建立面向未来的战略合作关系。本协议为框架协议，具体项目合作协 议，待双方协商确定后另行签署。 2、本次签署的《战略合作协议》对公司本年度经营业绩不会构成重大 影响，对公司未来年度经营业绩的影响将视公司与合作方后续签订的具体 项目协议以及实施情况而确定。 3、公司不存在最近三年披露的框架协议无进展或进展未达预期的情况。 一、战略框架协议签署概况 普洛药业股份有限公司(以下简称"普洛药业"或"公司")与百葵锐 （深圳）生物科技有限公司（以下简称"百葵锐"）本着诚信、平等、双赢 的原则开展合作，在现有产品、产能和技术上实现优势互补、强强合作。为 加强双方合作，建立面向未来的战略合作关系，双方愿意结成战略合作伙伴， 并于近日签订了《战略合作协议》。 本 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 6,428,714,752.29, representing a 7.96% increase compared to CNY 5,954,455,753.01 in the same period last year[11]. - The net profit attributable to shareholders was CNY 624,842,853.55, which is a 3.96% increase from CNY 601,065,331.00 in the previous year[11]. - The net cash flow from operating activities increased by 32.11% to CNY 980,781,274.48, up from CNY 742,373,240.68 in the same period last year[11]. - The total assets of the company at the end of the reporting period were CNY 13,515,257,382.48, a 5.86% increase from CNY 12,767,664,072.34 at the end of the previous year[11]. - The net assets attributable to shareholders increased by 1.78% to CNY 6,333,267,755.69 from CNY 6,222,728,875.43 at the end of the previous year[11]. - The basic earnings per share rose by 4.09% to CNY 0.5350, compared to CNY 0.5140 in the same period last year[11]. - The company achieved operating revenue of 642,871.48 million yuan, a year-on-year increase of 7.96%[17]. - The net profit attributable to shareholders reached 62,484.29 million yuan, reflecting a growth of 3.96% year-on-year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 60,239.48 million yuan, up 1.24% year-on-year[17]. Business Operations - The raw material intermediate business generated sales revenue of 470,442.27 million yuan, an increase of 11.89% year-on-year[18]. - The gross profit for the raw material intermediate business was 76,300.28 million yuan, with a gross margin of 16.22%, down 1.99% year-on-year[18]. - The company added 15 new clients in the raw material business during the reporting period, contributing to stable growth in multiple products[18]. - The CDMO business continued to strengthen its core competitiveness, with a growing number of clients and projects[18]. - The company has established CDMO R&D centers in Hengdian, Shanghai, and Boston, employing over 500 R&D personnel[18]. - The company reported a total of 731 quoted projects, a year-on-year increase of 51%, and 876 ongoing projects, up 44%, with 317 in the commercialization stage, reflecting a 28% growth[19]. - The CDMO business generated revenue of 1,027.54 million CNY, a decrease of 9.82%, with a gross profit of 411.93 million CNY, down 19.25%, resulting in a gross margin of 40.09%[19]. - The formulation business achieved revenue of 679.56 million CNY, an 18.37% increase, and a gross profit of 409.74 million CNY, up 41.67%, with a gross margin of 60.30%[20]. Research and Development - The company has 1,085 R&D personnel, with R&D expenses amounting to 314.77 million CNY, supporting its three major business segments[20]. - The company submitted 381 patent applications, holding 144 valid patents, including 133 invention patents, with 18 new invention patent applications filed during the reporting period[21]. - The company completed the construction of high-end API production workshops in March, enhancing its manufacturing capabilities[21]. - The company is in the design phase for a new peptide production line to meet market demand[21]. - The company has initiated 13 technical transformation projects to enhance automation and operational efficiency, significantly improving productivity[22]. - The company is leveraging AI technology in R&D and production processes to improve efficiency and operational management[22]. - The company plans to increase R&D investment to enhance core competitiveness in response to stricter regulations in the pharmaceutical industry[45]. - The company plans to increase its R&D budget by 25% in 2025 to support ongoing innovation and product development[186]. Environmental, Social, and Governance (ESG) - The company is committed to reducing pollution emissions and promoting green factory initiatives as part of its ESG strategy[24]. - The company has established a robust EHS management system in compliance with international standards to enhance safety and environmental protection[23]. - The company has a wastewater treatment system with an annual capacity of 5.4 million tons and 15 sets of RTO facilities with a total design processing capacity of 300,000 m³/h[23]. - The company has implemented various information systems, including RDMS and MES, to enhance R&D and production efficiency[22]. - The company has received various environmental management and energy-saving certifications, including B-level performance evaluation and "green factory" recognition[66]. - In the first half of 2024, the company established an ESG organizational structure to promote ESG-related work[67]. - The company has actively engaged in social responsibility initiatives, including setting up an "Employee Love Fund" to assist employees in need[70]. Financial Position - The company's cash and cash equivalents at the end of the reporting period amounted to CNY 3,948,093,757.21, accounting for 29.21% of total assets, an increase of 1.17% from the previous year[36]. - Accounts receivable increased to CNY 2,045,493,381.83, representing 15.13% of total assets, up by 1.85% year-over-year[36]. - Inventory decreased to CNY 1,750,809,080.60, accounting for 12.95% of total assets, down by 3.37% compared to the previous year[36]. - The company reported a total of 731 quoted projects, a year-on-year increase of 51%, and 876 ongoing projects, up 44%, with 317 in the commercialization stage, reflecting a 28% growth[19]. - The company has a total of CNY 3,377,139.48 in other comprehensive income for the half-year, contributing to the overall equity[117]. - The total assets at the end of the reporting period were CNY 2,475,206,612.58, showcasing the company's financial strength[117]. - The total liabilities at the end of the reporting period were CNY 1,296,683,119.67, indicating a manageable debt level relative to assets[117]. Shareholder Information - The company will not distribute cash dividends or issue bonus shares for the half-year period[49]. - The employee stock ownership plan includes 252 employees holding a total of 22,559,016 shares, representing 1.93% of the company's total equity[49]. - The company has distributed a total of 2,259.82 million CNY in cash dividends to shareholders, which is 35% of the net profit attributable to shareholders for the year[69]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.30% of the shares, totaling 330,941,729 shares, which are currently pledged[87]. - The total number of ordinary shareholders at the end of the reporting period was 44,077[87]. Market Outlook - The global pharmaceutical market is projected to reach $2,090.8 billion by 2030, driven by aging populations and increased healthcare awareness[15]. - China's pharmaceutical market is expected to reach 2.89 trillion yuan by 2030, accounting for 1/6 of the global market[15]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 15%[183]. - New product development includes the launch of two innovative drugs, expected to contribute an additional 300 million RMB in revenue by the end of 2024[186]. - The company is expanding its market presence, targeting an increase in market share by 5% in the next fiscal year[181]. Compliance and Governance - The company has not faced any administrative penalties for environmental issues during the reporting period[64]. - The company has not engaged in any significant related party transactions during the reporting period[72]. - The company has not experienced changes in senior management, including the appointment of a new general manager[48]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[72]. - The company has a comprehensive financial report approved by the board on August 14, 2024[127].

普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2024 年 7 月 16 日，普洛药业股份有限公司（以下简称"公司"）与中 国农业银行股份有限公司东阳市支行（以下简称"农业银行"）签订《保证合同》 （合同编号：33100120240011216），同意为公司全资子公司浙江普洛家园药业 有限公司（以下简称"家园药业"）与农业银行签署的《商业汇票银行承兑合同》 证券代码：000739 证券简称：普洛药业 公告编号：2024-40 （合同编号：33180120240010879）中的 3,000 万元银行承兑汇票提供连带责任 保证，担保期限 6 个月。 2、2024 年 7 月 18 日，公司与中国进出口银行浙江省分行（以下简称"进 出口银行"）签订《保证合同》[合同编号：（2024）进出银（浙信保）字第 3-003 号]，同意为公司全资子公司家园药业与进出口银行签署的《借款合同》[合同编 号：（2024）进出银（浙信合）字第 3-020 号]中的 3,000 万元出口卖方信贷提 供连带责任 ...

1、本次注销的回购股份数量为 9,199,916 股，占注销前公司总股本的 0.78%。 本次注销完成后，公司总股本将由 1,178,523,492 股变更为 1,169,323,576 股。 证券代码：000739 证券简称：普洛药业 公告编号：2024-36 普洛药业股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购股份 注销事宜已于 2024 年 6 月 3 日办理完成。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规 定，回购股份注销完成后，公司应当及时披露，并及时办理变更登记手续。现将公 司回购股份注销完成暨股份变动的具体情况公告如下： 一、本次回购股份的批准及实施情况 普洛药业股份有限公司（以下简称"公司"）于 2022 年 5 月 5 日召开第八届董 事会第十二次会议审议通过了《关于回购公司股份方案的议案》，同意公司以集中 竞价交易方式或法律法规允许的方式回购公司股份，用于实施公司股权激励或员工 ...

普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2024 年 5 月 15 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行东阳支行"）签订《保证合 同》（合同编号：横店 2024 年人保字 072 号），同意为公司全资子公司浙江普 洛家园药业有限公司（以下简称"家园药业"）与中国银行东阳支行签署的《流 动资金借款合同》（合同编号：横店 2024 年人借字 072 号）中的流动资金 5,000 万元提供连带责任保证，担保期限 12 个月。 证券代码：000739 证券简称：普洛药业 公告编号：2024-34 2、2024 年 5 月 15 日，公司与中国银行东阳支行签订《保证合同》（合同 编号：横店 2024 年人保字 071 号），同意为公司控股子公司浙江普洛康裕制药 有限公司（以下简称"康裕制药"）与中国银行东阳支行签署的《流动资金借款 合同》（合同编号：横店 2024 年人借字 071 号）中的流动资金 10,000 万元提供 连带责 ...

Financial Performance - The company reported sales revenue of ¥2,298,162,652.02, an increase of 15.1% compared to ¥1,996,810,525.10 in the previous period[4] - The company's operating revenue for Q1 2024 was CNY 3,198,046,619.86, representing a 3.65% increase compared to the same period last year[31] - Total operating revenue for the first quarter reached ¥3,198,046,619.86, an increase of 3.65% compared to ¥3,085,538,744.52 in the previous year[50] - The net profit attributable to shareholders was CNY 243,716,289.99, reflecting a 1.84% growth year-over-year[31] - Net profit attributable to the parent company was not explicitly stated but can be inferred from the financial data provided[41] Cash Flow - Total cash flow from operating activities for the current period was ¥280,125,473.87, an increase of 25.5% compared to ¥222,944,074.02 in the previous period[4] - The net cash flow from operating activities increased by 25.65% to CNY 280,125,473.87 compared to the previous year[31] - The company reported a net cash inflow from financing activities of ¥37,520,045.40, down from ¥102,872,647.96 in the previous year[53] - The net cash flow from financing activities decreased by 63.53% to CNY 37,520,045.40, attributed to a reduction in net borrowings[17] Assets and Liabilities - The total current assets at the end of the reporting period amounted to ¥9,054,659,617.92, up from ¥8,368,160,381.14 at the beginning of the period, reflecting a growth of 8.2%[3] - Total assets at the end of the reporting period reached CNY 13,476,350,661.11, a 5.55% increase from the end of the previous year[31] - Total assets increased to ¥13,476,350,661.11 from ¥12,767,664,072.34, representing a growth of approximately 5.56%[40] - The total liabilities at the end of the reporting period were ¥3,500,000,000.00, reflecting a stable financial position[3] - Total liabilities rose to ¥7,001,476,313.54, compared to ¥6,537,246,876.10, indicating an increase of about 7.09%[40] Equity - The company's equity attributable to shareholders rose to CNY 6,467,188,315.67, marking a 3.93% increase year-over-year[31] - The total equity attributable to shareholders increased to ¥6,467,188,315.67 from ¥6,222,728,875.43, reflecting a growth of approximately 3.93%[40] Inventory and Receivables - Accounts receivable rose to ¥2,034,676,951.20, up 20% from ¥1,695,032,971.13 in the previous period[3] - Inventory decreased to ¥1,871,338,432.27, down 10.2% from ¥2,083,301,418.08, indicating improved inventory management[3] Expenses - Total operating costs amounted to ¥2,862,663,780.78, up from ¥2,727,579,280.84, reflecting a year-over-year increase of 4.94%[50] - Research and development expenses decreased to ¥152,938,500.76 from ¥202,240,389.62, a reduction of approximately 24.38%[50] - Financial expenses showed a significant decrease of 120.80%, resulting in a gain of CNY -3,621,791.70 due to exchange rate gains[17] - Other income surged by 1466.73% to CNY 23,121,109.72, primarily due to an increase in policy-related income[17] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[5] - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[5]

证券代码：000739 证券简称：普洛药业 公告编号：2024-23 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个 交易日（即2024年3月27日）登记在册的前十名股东和前十名无限售条件股东名 称、持股数量及占总股本比例情况公告如下： | 序号 | 持股人名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 横店集团控股有限公司 | 330,941,729 | 28.08 | | 2 | 浙江横店进出口有限公司 | 156,552,903 | 13.28 | | 3 | 浙江横润科技有限公司 | 59,683,845 | 5.06 | | 4 | 横店集团家园化工有限公司 | 44,750,178 | 3.80 | | 5 | 普洛药业股份有限公司－第一期员工持股计划 | 22,559,016 | 1.91 | | 6 | 香港中央结算有限公司 | 19,830,013 | 1.68 | | | 中国工商银行股份有限公司－融通健康产业灵活配置混 | | ...

Financial Performance - The company's operating revenue for 2023 reached ¥11,474,162,365.59, representing an increase of 8.81% compared to the previous year[46]. - Net profit attributable to shareholders was ¥1,055,340,740.79, reflecting a growth of 6.69% year-over-year[46]. - The net profit after deducting non-recurring gains and losses was ¥1,026,437,851.58, which is a significant increase of 22.73% from the previous year[46]. - Basic and diluted earnings per share increased to ¥0.9025, up 7.12% from the previous year[46]. - Total assets at the end of 2023 were ¥12,767,664,072.34, marking a 6.21% increase from the end of 2022[46]. - Net assets attributable to shareholders increased by 12.90% to ¥6,222,728,875.43 compared to the end of 2022[46]. - The company achieved total revenue of ¥11,474,162,365.59, representing an 8.81% increase year-over-year[103]. - The pharmaceutical main business generated revenue of ¥11,440,239,653.78, with a year-over-year growth of 8.89%[103]. - The innovative drug R&D and production services segment saw a revenue increase of 27.10%, reaching ¥2,004,981,793.08[103]. - The gross profit margin for the pharmaceutical main business improved to 25.60%, up by 1.71% compared to the previous year[103]. Dividend Distribution - The company plans to distribute a cash dividend of 3.16 yuan per 10 shares to all shareholders, based on a total of 1,169,323,576 shares[9]. Business Operations - The company reported a significant change in its main business from retail to pharmaceutical chemicals since December 2001[26]. - The company has undergone a change in its registered address, which was updated in April 2019[41]. - The company has confirmed that there are no significant discrepancies in financial indicators compared to previously disclosed quarterly and semi-annual reports[29]. - The company has engaged He Xin Accounting Firm for auditing services during the reporting period[45]. - The company emphasizes that the annual report contains forward-looking statements and does not constitute a substantive commitment to investors[33]. - The company has stated that all board members attended the meeting to review the annual report, ensuring its accuracy and completeness[8]. - The company has acknowledged potential risks in future operations and has outlined corresponding countermeasures[14]. - The company’s stock is listed on the Shenzhen Stock Exchange under the code 000739[41]. Research and Development - The company invested RMB 624.87 million in R&D during the reporting period, representing a 17.25% increase and accounting for 5.45% of total revenue[77]. - The company has submitted 363 patent applications and held 139 valid patents by the end of the reporting period[59]. - The company has registered 9 API products and 2 formulation products during the reporting period, with 5 formulation products submitted for domestic registration[78]. - The company has developed new technology platforms such as PROTAC and ADC, which are currently under construction and partially operational[77]. - The company has established new CDMO R&D centers in Hangzhou, Shanghai, and Boston, with over 500 R&D personnel[121]. - R&D personnel increased to 1,205 in 2023, a growth of 17.45% from 1,026 in 2022[1]. - The number of R&D personnel with master's degrees rose by 41.82% to 312 in 2023, compared to 220 in 2022[1]. - The number of R&D personnel aged under 30 increased by 28.44% to 840 in 2023, compared to 654 in 2022[1]. Production and Capacity - The company has launched a new production line for cephalosporin powder injection with an annual capacity of 100 million bottles, which commenced production in April[81]. - The company aims to achieve a production line for solid formulations by March 2024[81]. - The company has implemented 17 automation projects to enhance operational efficiency during the reporting period[82]. - The company has established 11 wastewater treatment systems with a designed capacity of 5.4 million tons[84]. - Production volume of formulations rose by 25.69% to 110,738,310 units[125]. - API projects totaled 82, a 49% increase year-on-year, with 18 entering commercialization[120]. Market Presence and Client Development - The company expanded its international market presence, with products exported to over 70 countries and regions[114]. - The company has established BD offices in key global markets including Boston, Frankfurt, Tokyo, and Mumbai[114]. - The CDMO business has signed confidentiality agreements with 414 domestic and international innovative pharmaceutical companies, with 55% of clients from abroad[98]. - The company added 25 new clients in the raw material pharmaceutical business, indicating good progress in new customer development[94]. Environmental and Compliance - The company has built a comprehensive environmental management system in compliance with ISO standards, improving its EHS capabilities[84]. - The company has enhanced its operational efficiency, with all pharmaceutical production and distribution subsidiaries certified by NMPA and multiple facilities passing FDA and EU EDQM inspections[90]. Governance and Management - The company’s governance structure includes a board of directors and an audit committee responsible for internal and external audit supervision[180]. - The company’s management structure consists of three business units: API, CDMO, and FDF, aimed at enhancing operational efficiency[180]. - The annual shareholders' meeting had a participation rate of 61.94% on April 18, 2023[182]. - The company is focused on continuous improvement in its business operations and product strategies through a flat organizational structure[180]. - The board members attended a total of 6 board meetings, with an average attendance of 3 in person[199]. - Independent directors receive an annual allowance of 100,000 yuan each, as approved by the shareholders' meeting[196].